Research Articles | Page 4 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) Mar 2025 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough Jun 2023 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Mar 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management Jun 2023 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management Nov 2020 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond May 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab Aug 2020 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)